HELE · Helen of Troy Limited · Stock research

Current Thesis

The binary that framed the last note resolved on 2026-07-08, and the tape voted against the result. Q1 FY2027 beat on both lines — net sales $402.1M, +8.2% YoY against a consensus near $374.6M, adjusted diluted EPS $0.17 against a consensus of roughly breakeven — What got priced was the margin structure beneath the beat: gross margin 46.0% (-110bp YoY), adjusted operating margin 4.0% (-30bp), adjusted EBITDA margin 6.3% from 6.9%, and adjusted EPS of $0.17 against $0.41 in the year-ago quarter. Revenue recovered; the earnings power behind it did not.

The leg still standing is the balance sheet, and it is now the whole argument. Net leverage came in at 3.48x from 3.87x at the February year-end, total debt fell to $716.1M from $871.0M a year earlier, and management guided FY2027 free cash flow of $85–$100M with a year-end net-leverage target of 3.2x or lower. A $643.56M equity market cap sits beneath $716.1M of debt inside a $1.39B enterprise value — every turn of leverage retired lands disproportionately on the share line. At 7.55x forward earnings, that is what an investor is buying: a deleveraging stub priced as though the deleveraging is optional.

Since the print the stock has settled nothing. Seventeen sessions between the 2026-07-08 low of $25.13 and the 2026-07-28 high of $29.65, closing 2026-07-31 at $27.63 — above a 200-DMA of $21.15, marginally above a 50-DMA of $27.30, and above the Street's $26.50 average target. No scheduled print until roughly October.

Bullish and bearish views on Helen of Troy Limited

The model's bull view on Helen of Troy Limited (HELE), in brief: Deleveraging is measured, not just promised (2026-07-08): net leverage 3.48x versus 3.87x at the FY2026 close; total debt $716.1M versus $871.0M a year earlier. The bear view: The beat was sold (2026-07-08): -10.2% to $25.18. Both cases follow in full.

Bull Case

• Deleveraging is measured, not just promised (2026-07-08): net leverage 3.48x versus 3.87x at the FY2026 close; total debt $716.1M versus $871.0M a year earlier. Management attached a number to the next step — 3.2x or lower at fiscal year-end.
• Both segments grew (2026-07-08): Home & Outdoor $194.9M (+9.5%), Beauty & Wellness $207.2M (+7.0%). The FY2027 segment guide is $859–884M and $900–947M respectively.
• The guide was raised into a cautious consumer (2026-07-08): FY2027 net sales lifted to $1.759B–$1.831B (midpoint ~$1.795B) with adjusted EPS held at $3.25–$3.75.
• Cash conversion is guided to return (2026-07-08): FY2027 free cash flow of $85–$100M after Q1 printed -$6.4M, helped by ~$9.2M of phase-one tariff refunds expected for the year, of which the bulk of the remaining ~$7M was guided as collectible in Q2.
• Valuation carries the case: 7.55x forward, $643.56M market cap on 23.29M shares (2026-07-31), against FY2026 adjusted EBITDA of $185.8M and a brand set including OXO, Hydro Flask, Osprey, Braun, Vicks and Drybar.
• No insider selling into the recovery: the 2026 Form 4 record is restricted stock and tax withholding — CEO G. Scott Uzzell awarded 109,289 restricted shares on 2026-03-06 (direct holdings to 240,761); CFO Brian Grass had 1,288 shares withheld at $17.64 on 2026-03-01. No open-market insider sale appears on the record while the stock roughly doubled off its $13.85 52-week low.

Bear Case

• The beat was sold (2026-07-08): -10.2% to $25.18. A double beat that closes down double digits shifts the question from the quarter to the durability of the guide.
• Margins still moving the wrong way (2026-07-08): gross margin 46.0% (-110bp), adjusted operating margin 4.0% (-30bp), adjusted EPS $0.17 versus $0.41. The topline is being bought with margin.
• Cash flow inverted (2026-07-08): operations used $0.6M in Q1 FY2027 versus generating $58.3M in Q1 FY2026; free cash flow -$6.4M versus +$45.0M. The $85–$100M full-year guide now rests entirely on the remaining three quarters.
• Price sits through the Street (2026-07-29 to 07-31): consensus Hold, average one-year target $26.50, against a $27.63 close. Upside from here requires estimate revisions rather than multiple catch-up.
• Litigation names the sitting CFO (deadline 2026-08-03): a securities class action covering purchasers from 2024-04-24 through 2025-10-08 alleges Project Pegasus restructuring targets were publicly affirmed without the resources budgeted to hit them. CFO Brian Grass is a named individual defendant.
• GAAP and adjusted tell different stories: FY2026 (ended 2026-02-28) net sales $1,786.3M with an operating loss of $782.1M, net loss $899.0M, diluted loss per share $39.08; Q1 FY2027 GAAP EPS of $1.51 includes a ~$55M pre-tax gain on a Mississippi facility sale. The adjusted series is the only comparable one — which is precisely what the litigation contests.
• Supply-chain warning still live (2026-07-08): management flagged Middle East conflict as a potential disruption to supply and revenue, on top of tariff exposure.

Setup & Price Structure

Life-cycle: MATURING. What dates it: print-day and next-day volumes of 1,246,871 (2026-07-08) and 1,282,353 (2026-07-09) decayed to 287,532–390,333 across the final five sessions of July — participation contracting, not expanding. The structure is intact: a rising 200-DMA at $21.15 sits well beneath a $27.63 close, and the 2026-07-08 session low of $25.13 held the $25 line that has framed this name since June. But the fresh-attention phase is behind it — July's incremental research flow was four ratings touches (UBS and Canaccord 2026-07-09, Wall Street Zen 2026-07-12, Weiss 2026-07-21) resolving to a Hold consensus, which is coverage without a new bid.

Levels:

• $25.13 — 2026-07-08 intraday low, the post-print floor.
• $27.30 — 50-DMA at 2026-07-31; the close sat $0.33 above it.
• $29.65 / $30.34 — 2026-07-28 intraday high and 2026-07-01 high, the month's ceiling. 52-week range $13.85–$30.68.
• $21.15 — 200-DMA, the structural line beneath the recovery off $13.85.

Crowding and positioning, as observed rather than judged:

• Borrow of that size on a float this small cuts in both directions on any surprise.
• The 2026-07-31 close ($27.63) is above the consensus one-year target ($26.50).
• No earnings inside 30 days; the next print is roughly ten weeks out.
• An equity-issuance proposal is on the 2026-08-25 ballot — an amendment increasing shares available under the 2025 Stock Incentive Plan — after the stock roughly doubled off its 52-week low.
• The retail-facing headline clustering is plaintiff solicitation: SueWallSt (2026-06-11), The Gross Law Firm (2026-07-14, 2026-07-31), Levi & Korsinsky (2026-07-15, 2026-07-20, 2026-07-22) and Bragar Eagel (2026-07-27).

Catalyst Calendar (next 30 days)

• 2026-08-25, 10:00 a.m. EDT — Annual general meeting (virtual-only). Four items per the DEF 14A filed 2026-06-24: election of nine directors, advisory say-on-pay, an amendment increasing shares available under the 2025 Stock Incentive Plan, and appointment of Grant Thornton LLP as FY2027 auditor. The share-increase vote puts a number on planned issuance against 23.29M shares outstanding; say-on-pay reads shareholder tolerance for the reset after an $899.0M FY2026 net loss.
• ~2026-10-08 (est.) — Q2 FY2027 results for the quarter ending 2026-08-31 (prior-year Q2 was reported 2025-10-09). Outside the 30-day window. It is the first check on net leverage against the ≤3.2x year-end target, on whether gross margin stops eroding below 46.0%, and on collection of the ~$7M of phase-one tariff refunds guided into Q2.

Elapsed catalysts

• 2026-08-03 — Lead-plaintiff deadline, HELE securities class action. Court-set date for class-representative applications; class period 2024-04-24 to 2025-10-08. Nothing about the merits resolves here — the case consolidates, which starts the clock on legal expense and discovery-driven disclosure with the sitting CFO named individually. (passed 6d ago)

What Would Change Our Mind

The structure that has to hold is the post-print floor. The 2026-07-08 low of $25.13 and close of $25.18 sat five cents above the $25 line, and that line was approached again on 2026-07-23. A daily close below $25 forfeits that floor along with the 50-DMA near $27.30 and reopens the $21 area where the 200-DMA sits.

Three fundamental breaks, each observable on a date:

• Deleveraging stalls. Net leverage flat or above 3.48x at the Q2 print (~2026-10-08, est.), or the FY2027 free-cash-flow guide cut below $85M. The equity case here is arithmetic on debt reduction; at a 4.0% adjusted operating margin there is little else holding it up.
• Margin keeps compressing while the guide is held. Q2 gross margin printing below 46.0% with the $3.25–$3.75 adjusted EPS range unchanged would mean the guide depends on volume the consumer has not committed to.
• The theme flips to SATURATED. Mainstream deep-value coverage arriving while volume keeps contracting from the 1.25M print-day level, with price still above the $26.50 consensus target, would mark late-cycle flow into a thin bid.

The observable that would strengthen the case instead: a Q2 net-leverage print at or below 3.2x — ahead of the year-end target — with gross margin flat or better. That converts the balance-sheet argument from guidance into a trend and would force sell-side targets above the current $26.50 average.

Correlation Notes

Measured: beta 1.31 on a five-year basis (2026-07-31). Enterprise value $1.39B against $643.56M of equity value, so the shares behave as a levered claim — enterprise-level moves arrive amplified at the share line.

Inferred, and labelled as such. Three correlations run here. First, the small-cap levered-value cohort: with $716.1M of debt against $21.7M of cash at 2026-05-31, credit conditions and the front end of the rate curve matter more to this equity than to an unlevered peer. Second, the discretionary-durables complex — Newell Brands, YETI, Solo Brands, Spectrum Brands — on consumer-spending prints and retailer restocking commentary; Q1's +9.5% and +7.0% segment growth came off the same shelf space those names compete for. Third, the China-sourced import basket: phase-one refund timing is a shared line item across importers, and the ~$7M expected in Q2 is a policy-driven cash flow, not an operating one.

The 11.71% short-of-float reading (2026-07-31) adds an episodic fourth: on sessions when high-short-interest small caps move together, a 23.29M-share count means the move lands larger than the fundamentals warrant in either direction. That relationship is mechanical and carries no directional information.